Executive Summary
Azoth Analytics has released a research report titled "Global PD-L1 Biomarker Testing Market (2023 Edition)" which provides a complete analysis of the global PD-L1 Biomarker Testing industry in terms of market segmentation by Cancer Type (NSCLC, Kidney Cancer, Melanoma, Head and Neck, Bladder Cancer, Others), Assay Kit Type (PD-L1 22C3 IHC, PD-L1 28-8 IHC, PD-L1 SP263, PD-L1 SP142), and By End Use (Research and Development, Diagnostics), by region and by country for the historical period of 2019-2022, the estimates of 2023 and the forecast period of 2024-2029.
The research report covers a detailed analysis of the regions (Americas, Europe, APAC, Middle East Africa) and 10 countries (United States, Canada, Germany, United Kingdom, France, Italy, Spain, China, South Korea, Australia, Japan). Additionally, the research report presents data including market size, yearly growth and potential analysis, the competitive study of market players, investment opportunities and demand forecast. The research study also looks at the market growth indicators, restraints, supply and demand risk, and other important statistics, as well as a full assessment of current and future market trends that are relevant to the market evolution.
The Global PD-L1 Biomarker Testing Market is expected to generate USD 27.7 Billion by the end of 2029, up from USD 1.75 Billion in 2022. During the forecast period, 2024-2029, the Global PD-L1 Biomarker Testing market is expected to grow at a CAGR of 45.80%.
PD-L1 is a variety of proteins present on the cell membranes of numerous body cells. Some tumour cells contain a high concentration of PD-L1, which enables them to evade detection and elimination by the immune system. A PD-L1 assay determines the concentration of PD-L1 in cancerous cells.
The rising prevalence of different types of cancer around the world, and especially Lung cancer has been a major driver of the market for PD-L1 biomarker testing. Furthermore, as the demand for effective cancer treatments grows, pharmaceutical companies are driven to develop novel immunotherapies and invest in companion diagnostics such as PD-L1 tests. These tests are essential components of the regulatory approval procedure for novel pharmaceuticals, hence contributing to the expansion of the market. As more individuals are diagnosed with cancer, there has been a rising demand for efficient and targeted treatments, such as immunotherapies.
Scope of the Report:
• The report analyses the PD-L1 Biomarker Testing Market by Value (USD Million).
• The report presents the analysis of PD-L1 Biomarker Testing Market for the historical period of 2019-2022, the estimated year 2023 and the forecast period of 2024-2029.
• The report analyses the PD-L1 Biomarker Testing Market by Cancer Type (NSCLC, Kidney Cancer, Melanoma, Head & neck, Bladder Cancer, Other Cancer Types).
• The report analyses the PD-L1 Biomarker Testing Market by Assay Kit Type (PD-L1 22C3 IHC, PD-L1 28-8 IHC, PD-L1 (SP263), PD-L1 (SP142))
• The report analyses the PD-L1 Biomarker Testing Market by End Use (Research and Development, Diagnostics).
• The key insights of the report have been presented through the frameworks of SWOT and Porter's Five Forces Analysis. Also, the attractiveness of the market has been presented by region, by cancer type, by Assay Kits & by end uses.
• Also, the major opportunities, trends, drivers, and challenges of the industry have been analyzed in the report.
• The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include AstraZeneca PLC, Merck Group (SigmaAldrich Co., LLC), F. Hoffmann-La Roche AG, Abcam, Agilent technologies, NeoGenomics Laboratories, Inc., ACROBiosystems, PerkinElmer Inc., Guardant Health and Quanterix.
1. Market Background
1.1 Scope and Product Outlook
1.2 Executive Summary
1.3 Research Methodology
2. Strategic Recommendations
2.1 Advancement of PD-L1 Biomarker Testing via the Integration of Digital Pathology and Artificial Intelligence
2.2 Broad-Range Biomarker Analysis Panels
3. Global PD-L1 Biomarker Testing Market: Historic and Forecast (2019-2029)
3.1 PD-L1 Biomarker testing: Fact sheet
3.2 Age-standardised Cancer Incidence Rate, 2020
3.3 Global PD-(L)1 inhibitors sales by brand
3.4 Global Prevalence of Cancer, By Type
3.5 Global PD-L1 Biomarker Testing Market: Dashboard
3.6 Global PD-L1 Biomarker Testing Market: Market Value Assessment, 2019-2029 (USD Million)
3.7 Impact of COVID-19 on Global PD-L1 Biomarker Testing Market
3.8 Global PD-L1 Biomarker Testing Market Segmentation: By Cancer Type
3.8.1 Global PD-L1 Biomarker Testing Market, By Cancer Type Overview
3.8.2 Global PD-L1 Biomarker Testing Market Size, By NSCLC, By Value, 2019H-2029F (USD Million & CAGR)
3.8.3 Global PD-L1 Biomarker Testing Market Size, By Kidney Cancer, By Value, 2019H-2029F (USD Million & CAGR)
3.8.4 Global PD-L1 Biomarker Testing Market Size, By Melanoma, By Value, 2019H-2029F (USD Million & CAGR)
3.8.5 Global PD-L1 Biomarker Testing Market Size, By Head & neck, By Value, 2019H-2029F (USD Million & CAGR)
3.8.6 Global PD-L1 Biomarker Testing Market Size, By Bladder Cancer, By Value, 2019H-2029F (USD Million & CAGR)
3.8.7 Global PD-L1 Biomarker Testing Market Size, By Other Cancer Types, By Value, 2019H-2029F (USD Million & CAGR)
3.9 Global PD-L1 Biomarker Testing Market Segmentation: By Assay Kit Type
3.9.1 Global PD-L1 Biomarker Testing Market, By Assay Kit Type Overview
3.9.2 Global PD-L1 Biomarker Testing Market Size, By PD-L1 22C3 IHC, By Value, 2019H-2029F (USD Million & CAGR)
3.9.3 Global PD-L1 Biomarker Testing Market Size, By PD-L1 28-8 IHC, By Value, 2019H-2029F (USD Million & CAGR)
3.9.4 Global PD-L1 Biomarker Testing Market Size, By PD-L1 (SP263) , By Value, 2019H-2029F (USD Million & CAGR)
3.9.5 Global PD-L1 Biomarker Testing Market Size, By PD-L1 (SP142), By Value, 2019H-2029F (USD Million & CAGR)
3.10 Global PD-L1 Biomarker Testing Market Segmentation: By End Use
3.10.1 Global PD-L1 Biomarker Testing Market, By End Use Overview
3.10.2 Global PD-L1 Biomarker Testing Market Size, By Research and Development, By Value, 2019H-2029F (USD Million & CAGR)
3.10.3 Global PD-L1 Biomarker Testing Market Size, By Diagnostics, By Value, 2019H-2029F (USD Million & CAGR)
4. Global PD-L1 Biomarker Testing Market, Region Analysis
4.1 Regional Coverage of the Study
5. Americas PD-L1 Biomarker Testing Market: Historic and Forecast (2019-2029)
5.1 Americas PD-L1 Biomarker Testing Market: Snapshot
5.2 Americas PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
5.3 Americas PD-L1 Biomarker Testing Market: Key Factors
5.4 Americas PD-L1 Biomarker Testing Market Segmentation: By Cancer Type
5.4.1 Americas PD-L1 Biomarker Testing Market, By Cancer Type Overview
5.4.2 Americas PD-L1 Biomarker Testing Market Size, By NSCLC, By Value, 2019H-2029F (USD Million & CAGR)
5.4.3 Americas PD-L1 Biomarker Testing Market Size, By Kidney Cancer, By Value, 2019H-2029F (USD Million & CAGR)
5.4.4 Americas PD-L1 Biomarker Testing Market Size, By Melanoma, By Value, 2019H-2029F (USD Million & CAGR)
5.4.5 Americas PD-L1 Biomarker Testing Market Size, By Head & neck, By Value, 2019H-2029F (USD Million & CAGR)
5.4.6 Americas PD-L1 Biomarker Testing Market Size, By Bladder Cancer, By Value, 2019H-2029F (USD Million & CAGR)
5.4.7 Americas PD-L1 Biomarker Testing Market Size, By Other Cancer Types, By Value, 2019H-2029F (USD Million & CAGR)
5.5 Americas PD-L1 Biomarker Testing Market Segmentation: By Assay Kit Type
5.5.1 Americas PD-L1 Biomarker Testing Market, By Assay Kit Type Overview
5.5.2 Americas PD-L1 Biomarker Testing Market Size, By PD-L1 22C3 IHC, By Value, 2019H-2029F (USD Million & CAGR)
5.5.3 Americas PD-L1 Biomarker Testing Market Size, By PD-L1 28-8 IHC, By Value, 2019H-2029F (USD Million & CAGR)
5.5.4 Americas PD-L1 Biomarker Testing Market Size, By PD-L1 (SP263) , By Value, 2019H-2029F (USD Million & CAGR)
5.5.5 Americas PD-L1 Biomarker Testing Market Size, By PD-L1 (SP142), By Value, 2019H-2029F (USD Million & CAGR)
5.6 Americas PD-L1 Biomarker Testing Market Segmentation: By End Use
5.6.1 Americas PD-L1 Biomarker Testing Market, By End Use Overview
5.6.2 Americas PD-L1 Biomarker Testing Market Size, By Research and Development, By Value, 2019H-2029F (USD Million & CAGR)
5.6.3 Americas PD-L1 Biomarker Testing Market Size, By Diagnostics, By Value, 2019H-2029F (USD Million & CAGR)
5.7 Americas PD-L1 Biomarker Testing Market Segmentation: By Country
5.7.1 United States PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
5.7.1.1 United States PD-L1 Biomarker Testing Market, By Cancer Type
5.7.1.2 United States PD-L1 Biomarker Testing Market, By Assay Kit Type
5.7.1.3 United States PD-L1 Biomarker Testing Market, By End Use
5.7.2 Canada PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
5.7.2.1 Canada PD-L1 Biomarker Testing Market, By Cancer Type
5.7.2.2 Canada PD-L1 Biomarker Testing Market, By Assay Kit Type
5.7.2.3 Canada PD-L1 Biomarker Testing Market, By End Use
5.7.3 Rest of Americas PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
5.7.3.1 Rest of Americas PD-L1 Biomarker Testing Market, By Cancer Type
5.7.3.2 Rest of Americas PD-L1 Biomarker Testing Market, By Assay Kit Type
5.7.3.3 Rest of Americas PD-L1 Biomarker Testing Market, By End Use
6. Europe PD-L1 Biomarker Testing Market: Historic and Forecast (2019-2029)
6.1 Europe PD-L1 Biomarker Testing Market: Snapshot
6.2 Europe PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
6.3 Europe PD-L1 Biomarker Testing Market: Key Factors
6.4 Europe PD-L1 Biomarker Testing Market Segmentation: By Cancer Type
6.4.1 Europe PD-L1 Biomarker Testing Market, By Cancer Type Overview
6.4.2 Europe PD-L1 Biomarker Testing Market Size, By NSCLC, By Value, 2019H-2029F (USD Million & CAGR)
6.4.3 Europe PD-L1 Biomarker Testing Market Size, By Kidney Cancer, By Value, 2019H-2029F (USD Million & CAGR)
6.4.4 Europe PD-L1 Biomarker Testing Market Size, By Melanoma, By Value, 2019H-2029F (USD Million & CAGR)
6.4.5 Europe PD-L1 Biomarker Testing Market Size, By Head & neck, By Value, 2019H-2029F (USD Million & CAGR)
6.4.6 Europe PD-L1 Biomarker Testing Market Size, By Bladder Cancer, By Value, 2019H-2029F (USD Million & CAGR)
6.4.7 Europe PD-L1 Biomarker Testing Market Size, By Other Cancer Types, By Value, 2019H-2029F (USD Million & CAGR)
6.5 Europe PD-L1 Biomarker Testing Market Segmentation: By Assay Kit Type
6.5.1 Europe PD-L1 Biomarker Testing Market, By Assay Kit Type Overview
6.5.2 Europe PD-L1 Biomarker Testing Market Size, By PD-L1 22C3 IHC, By Value, 2019H-2029F (USD Million & CAGR)
6.5.3 Europe PD-L1 Biomarker Testing Market Size, By PD-L1 28-8 IHC, By Value, 2019H-2029F (USD Million & CAGR)
6.5.4 Europe PD-L1 Biomarker Testing Market Size, By PD-L1 (SP263) , By Value, 2019H-2029F (USD Million & CAGR)
6.5.5 Europe PD-L1 Biomarker Testing Market Size, By PD-L1 (SP142), By Value, 2019H-2029F (USD Million & CAGR)
6.6 Europe PD-L1 Biomarker Testing Market Segmentation: By End Use
6.6.1 Europe PD-L1 Biomarker Testing Market, By End Use Overview
6.6.2 Europe PD-L1 Biomarker Testing Market Size, By Research and Development, By Value, 2019H-2029F (USD Million & CAGR)
6.6.3 Europe PD-L1 Biomarker Testing Market Size, By Diagnostics, By Value, 2019H-2029F (USD Million & CAGR)
6.7 Europe PD-L1 Biomarker Testing Market Segmentation: By Country
6.7.1 Germany PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
6.7.1.1 Germany PD-L1 Biomarker Testing Market, By Cancer Type
6.7.1.2 Germany PD-L1 Biomarker Testing Market, By Assay Kit Type
6.7.1.3 Germany PD-L1 Biomarker Testing Market, By End Use
6.7.2 United Kingdom PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
6.7.2.1 United Kingdom PD-L1 Biomarker Testing Market, By Cancer Type
6.7.2.2 United Kingdom PD-L1 Biomarker Testing Market, By Assay Kit Type
6.7.2.3 United Kingdom PD-L1 Biomarker Testing Market, By End Use
6.7.3 France PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
6.7.3.1 France PD-L1 Biomarker Testing Market, By Cancer Type
6.7.3.2 France PD-L1 Biomarker Testing Market, By Assay Kit Type
6.7.3.3 France PD-L1 Biomarker Testing Market, By End Use
6.7.4 Italy PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
6.7.4.1 Italy PD-L1 Biomarker Testing Market, By Cancer Type
6.7.4.2 Italy PD-L1 Biomarker Testing Market, By Assay Kit Type
6.7.4.3 Italy PD-L1 Biomarker Testing Market, By End Use
6.7.5 Spain PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
6.7.5.1 Spain PD-L1 Biomarker Testing Market, By Cancer Type
6.7.5.2 Spain PD-L1 Biomarker Testing Market, By Assay Kit Type
6.7.5.3 Spain PD-L1 Biomarker Testing Market, By End Use
6.7.6 Rest of Europe PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
6.7.6.1 Rest of Europe PD-L1 Biomarker Testing Market, By Cancer Type
6.7.6.2 Rest of Europe PD-L1 Biomarker Testing Market, By Assay Kit Type
6.7.6.3 Rest of Europe PD-L1 Biomarker Testing Market, By End Use
7. Asia-Pacific PD-L1 Biomarker Testing Market: Historic and Forecast (2019-2029)
7.1 Asia-Pacific PD-L1 Biomarker Testing Market: Snapshot
7.2 Asia-Pacific PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
7.3 Asia-Pacific PD-L1 Biomarker Testing Market: Key Factors
7.4 Asia-Pacific PD-L1 Biomarker Testing Market Segmentation: By Cancer Type
7.4.1 Asia-Pacific PD-L1 Biomarker Testing Market, By Cancer Type Overview
7.4.2 Asia-Pacific PD-L1 Biomarker Testing Market Size, By NSCLC, By Value, 2019H-2029F (USD Million & CAGR)
7.4.3 Asia-Pacific PD-L1 Biomarker Testing Market Size, By Kidney Cancer, By Value, 2019H-2029F (USD Million & CAGR)
7.4.4 Asia-Pacific PD-L1 Biomarker Testing Market Size, By Melanoma, By Value, 2019H-2029F (USD Million & CAGR)
7.4.5 Asia-Pacific PD-L1 Biomarker Testing Market Size, By Head & neck, By Value, 2019H-2029F (USD Million & CAGR)
7.4.6 Asia-Pacific PD-L1 Biomarker Testing Market Size, By Bladder Cancer, By Value, 2019H-2029F (USD Million & CAGR)
7.4.7 Asia-Pacific PD-L1 Biomarker Testing Market Size, By Other Cancer Types, By Value, 2019H-2029F (USD Million & CAGR)
7.5 Asia-Pacific PD-L1 Biomarker Testing Market Segmentation: By Assay Kit Type
7.5.1 Asia-Pacific PD-L1 Biomarker Testing Market, By Assay Kit Type Overview
7.5.2 Asia-Pacific PD-L1 Biomarker Testing Market Size, By PD-L1 22C3 IHC, By Value, 2019H-2029F (USD Million & CAGR)
7.5.3 Asia-Pacific PD-L1 Biomarker Testing Market Size, By PD-L1 28-8 IHC, By Value, 2019H-2029F (USD Million & CAGR)
7.5.4 Asia-Pacific PD-L1 Biomarker Testing Market Size, By PD-L1 (SP263) , By Value, 2019H-2029F (USD Million & CAGR)
7.5.5 Asia-Pacific PD-L1 Biomarker Testing Market Size, By PD-L1 (SP142), By Value, 2019H-2029F (USD Million & CAGR)
7.6 Asia-Pacific PD-L1 Biomarker Testing Market Segmentation: By End Use
7.6.1 Asia-Pacific PD-L1 Biomarker Testing Market, By End Use Overview
7.6.2 Asia-Pacific PD-L1 Biomarker Testing Market Size, By Research and Development, By Value, 2019H-2029F (USD Million & CAGR)
7.6.3 Asia-Pacific PD-L1 Biomarker Testing Market Size, By Diagnostics, By Value, 2019H-2029F (USD Million & CAGR)
7.7 Europe PD-L1 Biomarker Testing Market Segmentation: By Country
7.7.1 China PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
7.7.1.1 China PD-L1 Biomarker Testing Market, By Cancer Type
7.7.1.2 China PD-L1 Biomarker Testing Market, By Assay Kit Type
7.7.1.3 China PD-L1 Biomarker Testing Market, By End Use
7.7.2 Japan PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
7.7.2.1 Japan PD-L1 Biomarker Testing Market, By Cancer Type
7.7.2.2 Japan PD-L1 Biomarker Testing Market, By Assay Kit Type
7.7.2.3 Japan PD-L1 Biomarker Testing Market, By End Use
7.7.3 South Korea PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
7.7.3.1 South Korea PD-L1 Biomarker Testing Market, By Cancer Type
7.7.3.2 South Korea PD-L1 Biomarker Testing Market, By Assay Kit Type
7.7.3.3 South Korea PD-L1 Biomarker Testing Market, By End Use
7.7.4 Australia PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
7.7.4.1 Australia PD-L1 Biomarker Testing Market, By Cancer Type
7.7.4.2 Australia PD-L1 Biomarker Testing Market, By Assay Kit Type
7.7.4.3 Australia PD-L1 Biomarker Testing Market, By End Use
7.7.5 Rest of Asia Pacific PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
7.7.5.1 Rest of Asia Pacific PD-L1 Biomarker Testing Market, By Cancer Type
7.7.5.2 Rest of Asia Pacific PD-L1 Biomarker Testing Market, By Assay Kit Type
7.7.5.3 Rest of Asia Pacific PD-L1 Biomarker Testing Market, By End Use
8. Middle-East & Africa PD-L1 Biomarker Testing Market: Historic and Forecast (2019-2029)
8.1 Middle-East & Africa PD-L1 Biomarker Testing Market: Snapshot
8.2 Middle-East & Africa PD-L1 Biomarker Testing Market: Market Size and CAGR, 2019-2029 (USD Million & CAGR)
8.3 Middle-East & Africa PD-L1 Biomarker Testing Market: Key Factors
8.4 Middle-East & Africa PD-L1 Biomarker Testing Market Segmentation: By Cancer Type
8.4.1 Middle-East & Africa PD-L1 Biomarker Testing Market, By Cancer Type Overview
8.4.2 Middle-East & Africa PD-L1 Biomarker Testing Market Size, By NSCLC, By Value, 2019H-2029F (USD Million & CAGR)
8.4.3 Middle-East & Africa PD-L1 Biomarker Testing Market Size, By Kidney Cancer, By Value, 2019H-2029F (USD Million & CAGR)
8.4.4 Middle-East & Africa PD-L1 Biomarker Testing Market Size, By Melanoma, By Value, 2019H-2029F (USD Million & CAGR)
8.4.5 Middle-East & Africa PD-L1 Biomarker Testing Market Size, By Head & neck, By Value, 2019H-2029F (USD Million & CAGR)
8.4.6 Middle-East & Africa PD-L1 Biomarker Testing Market Size, By Bladder Cancer, By Value, 2019H-2029F (USD Million & CAGR)
8.4.7 Middle-East & Africa PD-L1 Biomarker Testing Market Size, By Other Cancer Types, By Value, 2019H-2029F (USD Million & CAGR)
8.5 Middle-East & Africa PD-L1 Biomarker Testing Market Segmentation: By Assay Kit Type
8.5.1 Middle-East & Africa PD-L1 Biomarker Testing Market, By Assay Kit Type Overview
8.5.2 Middle-East & Africa PD-L1 Biomarker Testing Market Size, By PD-L1 22C3 IHC, By Value, 2019H-2029F (USD Million & CAGR)
8.5.3 Middle-East & Africa PD-L1 Biomarker Testing Market Size, By PD-L1 28-8 IHC, By Value, 2019H-2029F (USD Million & CAGR)
8.5.4 Middle-East & Africa PD-L1 Biomarker Testing Market Size, By PD-L1 (SP263) , By Value, 2019H-2029F (USD Million & CAGR)
8.5.5 Middle-East & Africa PD-L1 Biomarker Testing Market Size, By PD-L1 (SP142), By Value, 2019H-2029F (USD Million & CAGR)
8.6 Middle-East & Africa PD-L1 Biomarker Testing Market Segmentation: By End Use
8.6.1 Middle-East & Africa PD-L1 Biomarker Testing Market, By End Use Overview
8.6.2 Middle-East & Africa PD-L1 Biomarker Testing Market Size, By Research and Development, By Value, 2019H-2029F (USD Million & CAGR)
8.6.3 Middle-East & Africa PD-L1 Biomarker Testing Market Size, By Diagnostics, By Value, 2019H-2029F (USD Million & CAGR)
9. Market Dynamics
9.1 Impact Assessment of Market Dynamics on Global PD-L1 Biomarker Testing Market
9.2 Drivers
9.3 Restraints
9.4 Trends
10. Porter's Five Forces Analysis
11. Competitive Positioning
11.1 Companies' Product Positioning
11.2 Market Position Matrix
11.3 Market Share Analysis of PD-L1 Biomarker Testing Market
11.4 Company Profiles
11.4.1 AstraZeneca PLC
11.4.2 Merck Group (SigmaAldrich Co., LLC)
11.4.3 F. Hoffmann-La Roche AG
11.4.4 Abcam
11.4.5 Agilent technologies
11.4.6 NeoGenomics Laboratories, Inc.,
11.4.7 ACROBiosystems
11.4.8 PerkinElmer Inc.
11.4.9 Guardant Health
11.4.10 Quanterix
The Intelligent Driver Testing and Training System Market is set to witness immense growth during the forecast period 2024-2031. This intelligence report offers an in-depth analysis of the market size, share, growth, opportunity, competitive...
The Driver Training and Testing System Market is set to witness immense growth during the forecast period 2024-2031. This intelligence report offers an in-depth analysis of the market size, share, growth, opportunity, competitive landscape, ...
The Blood Relationship Testing Service Market is set to witness immense growth during the forecast period 2024-2031. This intelligence report offers an in-depth analysis of the market size, share, growth, opportunity, competitive landscape, ...
The Residual Seal Force Testing Services Market is set to witness immense growth during the forecast period 2024-2031. This intelligence report offers an in-depth analysis of the market size, share, growth, opportunity, competitive landscape...
The Combustion Toxicity Testing Services Market is set to witness immense growth during the forecast period 2024-2031. This intelligence report offers an in-depth analysis of the market size, share, growth, opportunity, competitive landscape...
The Concept Development and Testing Service Market is set to witness immense growth during the forecast period 2024-2031. This intelligence report offers an in-depth analysis of the market size, share, growth, opportunity, competitive landsc...
The Personal Care and Daily Chemical Testing Market is set to witness immense growth during the forecast period 2024-2031. This intelligence report offers an in-depth analysis of the market size, share, growth, opportunity, competitive lands...
The Software Compliance Testing Services Market is set to witness immense growth during the forecast period 2024-2031. This intelligence report offers an in-depth analysis of the market size, share, growth, opportunity, competitive landscape...
The Microbiological Water Testing Services Market is set to witness immense growth during the forecast period 2024-2031. This intelligence report offers an in-depth analysis of the market size, share, growth, opportunity, competitive landsca...
The Smartwatch Automated Testing Solution Market is set to witness immense growth during the forecast period 2024-2031. This intelligence report offers an in-depth analysis of the market size, share, growth, opportunity, competitive landscap...